Q-linea AB (publ) (STO:QLINEA)

Market Cap	407.00M
Revenue (ttm)	9.53M
Net Income (ttm)	-183.79M
Shares Out	6.43B
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,014,089
Average Volume	32,776,779
Open	0.0656
Previous Close	0.0633
Day's Range	0.0600 - 0.0656
52-Week Range	0.0304 - 4.6900
Beta	1.00
RSI	57.62
Earnings Date	Jul 10, 2025

About Q-linea AB

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom and European Union. The company offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Employees: 94
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLINEA

Financial Performance

In 2024, Q-linea AB's revenue was 4.14 million, a decrease of -25.21% compared to the previous year's 5.53 million. Losses were -216.87 million, -5.45% less than in 2023.